Identification of imidazole-based small molecules to combat cognitive disability caused by Alzheimer’s disease: : A molecular docking and MD simulations based approach
Graphical Abstract
Display Omitted
References
[1]
P. Banerjee, F.O. Dehnbostel, R. Preissner, Prediction is a balancing act: importance of sampling methods to balance sensitivity and specificity of predictive models based on imbalanced chemical data sets, Front. Chem. 6 (2018).
[2]
P. Banerjee, A.O. Eckert, A.K. Schrey, R. Preissner, ProTox-II: a webserver for the prediction of toxicity of chemicals, Nucleic Acids Res 46 (W1) (2018) W257–W263.
[3]
M. Buchholz, U. Heiser, S. Schilling, A.J. Niestroj, K. Zunkel, H.-U. Demuth, The first potent inhibitors for human glutaminyl cyclase: synthesis and structure− activity relationship, J. Med Chem. 49 (2) (2006) 664–677.
[4]
J.R. Coimbra, P.I. Moreira, A.E. Santos, J.A. Salvador, Therapeutic potential of glutaminyl cyclases: current status and emerging trends, Drug Discov. Today (2023).
[5]
J.R. Coimbra, P.J. Sobral, A.E. Santos, P.I. Moreira, J.A. Salvador, An overview of glutaminyl cyclase inhibitors for Alzheimer’s disease, Future Med. Chem. 11 (24) (2019) 3179–3194.
[6]
W.L. DeLano, Pymol: An open-source molecular graphics tool, CCP4 Newsl. Protein Crystallogr 40 (1) (2002) 82–92.
[7]
K. Dileep, N. Sakai, K. Ihara, M. Kato-Murayama, A. Nakata, A. Ito, D. Sivaraman, J.W. Shin, M. Yoshida, M. Shirouzu, Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminyl cyclase inhibitors, Int. J. Biol. Macromol. 170 (2021) 415–423.
[8]
F. DiPisa, C. Pozzi, M. Benvenuti, M. Andreini, G. Marconi, S. Mangani, The soluble Y115E–Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease, Acta Crystallogr. Sect. F Struct. Biol. Commun. 71 (8) (2015) 986–992.
[9]
M.N. Drwal, P. Banerjee, M. Dunkel, M.R. Wettig, R. Preissner, ProTox: a web server for the in silico prediction of rodent oral toxicity, Nucleic Acids Res. 42 (W1) (2014) W53–W58.
[10]
R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, Glide: a new approach for rapid, accurate docking and scoring. 1, Method Assess. docking Accuracy J. Med. Chem. 47 (7) (2004) 1739–1749.
[11]
S. Gatfaoui, N. Issaoui, A. Mezni, F. Bardak, T. Roisnel, A. Atac, H. Marouani, Synthesis, structural and spectroscopic features, and investigation of bioactive nature of a novel organic-inorganic hybrid material 1H-1, 2, 4-triazole-4-ium trioxonitrate, J. Mol. Struct. 1150 (2017) 242–257.
[12]
N. Guex, M.C. Peitsch, SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling, electrophoresis 18 (15) (1997) 2714–2723.
[13]
A.P. Gunn, B.X. Wong, C. McLean, C. Fowler, P.J. Barnard, J.A. Duce, B.R. Roberts, A.R. Group, Increased glutaminyl cyclase activity in brains of Alzheimer’s disease individuals, J. Neurochem. 156 (6) (2021) 979–987.
[14]
F. Hammami, N. Issaoui, S. Nasr, Investigation of hydrogen bonded structure of urea-water mixtures through Infra-red spectroscopy and non-covalent interaction (NCI) theoretical approach, Comput. Theor. Chem. 1199 (2021).
[15]
K.-F. Huang, Y.-L. Liu, W.-J. Cheng, T.-P. Ko, A.H.-J. Wang, Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation, Proc. Natl. Acad. Sci. 102 (37) (2005) 13117–13122.
[16]
S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B.A. Shoemaker, PubChem substance and compound databases, Nucleic Acids Res. 44 (D1) (2016) D1202–D1213.
[17]
K. Küçükoğlu, Y.G. AÇIL, Glutaminyl cyclase and its inhibitors, Int. J. Innov. Res. Rev. 6 (1) (2022) 59–75.
[18]
Ye Liu, Y. Shi, P. Wang, Functions of glutaminyl cyclase and its isoform in diseases, Vis. Cancer Med. 4 (2023) 1.
[19]
P. Mark, L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K, J. Phys. Chem. A 105 (43) (2001) 9954–9960.
[20]
G.J. Martyna, D.J. Tobias, M.L. Klein, Constant pressure molecular dynamics algorithms, J. Chem. Phys. 101 (5) (1994) 4177–4189.
[21]
M. Medimagh, C.B. Mleh, N. Issaoui, A.S. Kazachenko, T. Roisnel, O.M. Al-Dossary, H. Marouani, L.G. Bousiakoug, DFT and molecular docking study of the effect of a green solvent (water and DMSO) on the structure, MEP, and FMOs of the 1-ethylpiperazine-1, 4-diium bis (hydrogenoxalate) compound, J. Mol. Liq. 369 (2023).
[22]
N. Mhadhbi, N. Issaoui, W.S. Hamadou, J.M. Alam, A.S. Elhadi, M. Adnan, H. Naϊli, R. Badraoui, Physico-chemical properties, pharmacokinetics, molecular docking and in-vitro pharmacological study of a cobalt (II) complex based on 2-aminopyridine, ChemistrySelect 7 (3) (2022).
[23]
T. Morishita, From Nosé–Hoover chain to Nosé–Hoover network: design of non-Hamiltonian equations of motion for molecular-dynamics with multiple thermostats, Mol. Phys. 108 (10) (2010) 1337–1347.
[24]
E. Nichols, C.E. Szoeke, S.E. Vollset, N. Abbasi, F. Abd-Allah, J. Abdela, M.T.E. Aichour, R.O. Akinyemi, F. Alahdab, S.W. Asgedom, Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol. 18 (1) (2019) 88–106.
[25]
T. Qassem, L. Itani, W. Nasr, D. Al-Ayyat, S.F. Javaid, H. Al-Sinawi, Prevalence and economic burden of dementia in the Arab world, BJPsych Open 9 (4) (2023).
[26]
C. Qiu, M. Kivipelto, E. Von Strauss, Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention, Dialog. Clin. Neurosci. 11 (2) (2009) 111–128.
[27]
M.P. Repasky, M. Shelley, R.A. Friesner, Flexible ligand docking with Glide, Curr. Protoc. Bioinforma. 18 (1) (2007) 8.12. 11-18.12. 36.
[28]
D. Romani, O. Noureddine, N. Issaoui, S.A. Brandán, Properties and reactivities of niclosamide in different media, a potential antiviral to treatment of COVID-19 by using DFT calculations and molecular docking, Biointerface Res. Appl. Chem. 10 (6) (2020) 7295–7328.
[29]
S. Schilling, A.J. Niestroj, J.-U. Rahfeld, T. Hoffmann, M. Wermann, K. Zunkel, C. Wasternack, H.-U. Demuth, Identification of human glutaminyl cyclase as a metalloenzyme: potent inhibition by imidazole derivatives and heterocyclic chelators, J. Biol. Chem. 278 (50) (2003) 49773–49779.
[30]
D. Shivakumar, E. Harder, W. Damm, R.A. Friesner, W. Sherman, Improving the prediction of absolute solvation free energies using the next generation OPLS force field, J. Chem. Theory Comput. 8 (8) (2012) 2553–2558.
[31]
G. Sliwoski, S. Kothiwale, J. Meiler, E.W. Lowe, Computational methods in drug discovery, Pharmacol. Rev. 66 (1) (2014) 334–395.
[32]
S.F. Sousa, P.A. Fernandes, M.J. Ramos, Protein–ligand docking: current status and future challenges, Protein.: Struct., Funct., Bioinforma. 65 (1) (2006) 15–26.
[33]
T. Sterling, J.J. Irwin, ZINC 15–ligand discovery for everyone, J. Chem. Inf. Model. 55 (11) (2015) 2324–2337.
[34]
UniProt: the universal protein knowledgebase (2017). Nucleic acids research 45 (D1):D158-D169.
[35]
D.K. Vijayan, K.Y. Zhang, Human glutaminyl cyclase: structure, function, inhibitors and involvement in Alzheimer’s disease, Pharmacol. Res. 147 (2019).
[36]
X. Wang, L. Wang, X. Yu, Y. Li, Z. Liu, Y. Zou, Y. Zheng, Z. He, H. Wu, Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice, Int. Immunopharmacol. 75 (2019).
[37]
A. Waterhouse, M. Bertoni, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, F.T. Heer, T.A.P. de Beer, C. Rempfer, L. Bordoli, SWISS-MODEL: homology modelling of protein structures and complexes, Nucleic Acids Res. 46 (W1) (2018) W296–W303.
[38]
C. Xu, Y.-n Wang, H. Wu, Glutaminyl cyclase, diseases, and development of glutaminyl cyclase inhibitors, J. Med. Chem. 64 (10) (2021) 6549–6565.
[39]
P.V. Zadorozhnii, V.V. Kiselev, A.V. Kharchenko, In silico ADME profiling of salubrinal and its analogues, Future Pharmacol. 2 (2) (2022) 160–197.
[40]
Q. Zhou, J. Cai, F. Qin, J. Liu, C. Li, W. Xiong, Y. Wang, C. Xu, H. Wu, Discovery of potential scaffolds for glutaminyl cyclase inhibitors: Virtual screening, synthesis, and evaluation, Biorg Med. Chem. 97 (2024).
Index Terms
- Identification of imidazole-based small molecules to combat cognitive disability caused by Alzheimer’s disease: A molecular docking and MD simulations based approach
Index terms have been assigned to the content through auto-classification.
Recommendations
Docking assay of small molecule antivirals to p7 of HCV
Display Omitted Binding poses of antivirals to monomers and hexameric bundles of p7 of HCV.Guanidine based ligands bind better than derivatives of adamantanes and iminosugars.Binding of the best candidates is at the site of the loop.Hydrogen bonding and ...
Small molecule ligand docking to genotype specific bundle structures of hepatitis C virus (HCV) p7 protein
Display Omitted Binding poses of antivirals to hexameric bundles of p7 of HCV genotype 5a and 1b.LeadIT suggests guanidinium compounds then imino sugars, adamantanes.Rescoring with HYDE reverses the order.Favored binding sites within the pore and at ...
FSHR activation through small molecule modulators: Mechanistic insights from MD simulations
AbstractFollicle-stimulating hormone receptor (FSHR) is a glycoprotein hormone receptor that plays a vital role in reproduction, cancer progression and osteoporosis. Owing to its therapeutic importance, several small molecule modulators have been ...
Graphical abstractDisplay Omitted
Highlights- FSHR agonist and antagonist allosteric modulators interact via same TMD pocket.
- Both agonist and antagonist interacts with few distinct residues at TMD pocket.
- FSHR(TMD) residues Ile522, Ala595, Ile602 & Val604 interact only with ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
Elsevier Ltd.
Publisher
Elsevier Science Publishers B. V.
Netherlands
Publication History
Published: 21 November 2024
Author Tags
Qualifiers
- Research-article
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 0Total Downloads
- Downloads (Last 12 months)0
- Downloads (Last 6 weeks)0
Reflects downloads up to 27 Nov 2024
Other Metrics
Citations
View Options
View options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign in